Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0049

Scientific exchange · Dr. Emiko Olsen

16 Jan 2026 · Virtual · Dr. Emiko Olsen, IEO Milano · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0049—

Capture insight from this engagement

Location: IEO Milano
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Comparator checkpoint monotherapy
Elderly / ECOG 2 patients

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at IEO Milano. Discussed comparator checkpoint monotherapy, elderly / ecog 2 patients.

Insights captured (1)

Capture insight

INS-0075High
Comparator checkpoint monotherapy
Comparator checkpoint monotherapy: gap in current materials reported by thoracic medical oncologist (IT).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 5
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0049

Audit history (0)

All create, update and approval events for this record

No audit events in sample data